Vera Therapeutics is trading at $30.69, down -4.00%, amid broad risk-off selling and biotech-sector weakness.

  • No company-specific announcement explaining the November 5 move surfaced; third-quarter results are scheduled after the market closes.
  • Reuters reported sharp technology losses and investor concerns about AI spending and data-center scrutiny.
  • The supplied sector update reports XBI down 5.19% during the regular session.